Journal
EARLY INTERVENTION IN PSYCHIATRY
Volume 15, Issue 3, Pages 585-594Publisher
WILEY
DOI: 10.1111/eip.12988
Keywords
clinical high-risk syndrome of psychosis; conversion rate; prodromal psychosis; randomized controlled trial; sulforaphane
Categories
Funding
- Ministry of Science and Technology of China, National Key R&D Program of China [2016YFC1306800]
- Multi-center Clinical Research Program of Shanghai Jiaotong University School of Medicine [DLY201817]
- National Nature Science Foundation of China [81361120403, 81671332, 81671329, 81871050]
Ask authors/readers for more resources
This study aims to evaluate the efficacy of SFN in improving prodromal symptoms and reducing the risk and conversion rate of psychosis among individuals at clinical high risk (CHR) for psychosis, through a randomized, double-blind, placebo-controlled, multi-center trial.
Aim A growing number of studies suggest a role of neuroinflammation and oxidative stress in the pathophysiology of psychosis. Sulforaphane (SFN), a natural compound extracted from cruciferous vegetables, has shown anti-inflammatory and anti-oxidative effects which imply a potential effect on decreasing the risk of psychosis. However, there is no study testing the efficacy of SFN for this purpose. It's necessary to evaluate its efficacy on individuals at clinical high risk (CHR) for psychosis. Methods This is a randomized, double-blind, placebo-controlled, multi-centre trial. A total of 300 CHR subjects will be identified in the course of face-to-face interviews using the Structured Interview for Prodromal Syndromes. All participants will be randomly allocated to SFN group (n = 150) or placebo group (n = 150). The study duration includes an intervention for 52 consecutive weeks, and additional 1-year follow-up. Results The primary outcome is 2-year conversion rate of psychosis. Secondary outcomes include 1-year conversion rate of psychosis, the severity and duration of prodromal symptoms, predictive risk of psychosis conversion, neurocognitive functioning and peripheral blood biomarkers of inflammation, oxidative stress and metabolism. Safety monitoring will be performed using scales for side effect, serious adverse events recording, and laboratory tests. Conclusion This trial is expected to clarify the efficacy of SFN in improving prodromal symptoms, and its role in decreasing the risk and conversion rate of psychosis among CHR subjects. The results will also provide solid evidence about the efficacy and safety of SFN in CHR population. Potential challenges and their solutions in performing the present trial are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available